SAFE & EFFECTIVE

17th September 2021

     

Font size: - +

The evidence continues to mount in favour of the effectiveness of the vaccines being used in South Africa. While most people have received the Pfizer-BioNTech vaccine, which was the first to receive the full approval of the US Food and Drug Administration in August, recent news on the efficacy, in South Africa, of the Johnson & Johnson (J&J) is positive. The vaccine was used during the Sisonke trial to vaccinate about half-a-million South African health workers. Sisonke study co-leader Glenda Gray told Bloomberg this month that soon-to-be-published research showed that the J&J vaccine cuts the risk of getting infected by about half, while the vast majority of the breakthrough infections were mild. Photograph: Bloomberg

Edited by Creamer Media Reporter

Comments

The functionality you are trying to access is only available to subscribers.

If you are already a subscriber, you can Login Here.

If you are not a subscriber, you can subscribe now, by selecting one of the below options.

For more information or assistance, please contact us at subscriptions@creamermedia.co.za.

Option 1 (equivalent of R125 a month):

Receive a weekly copy of Creamer Media's Engineering News & Mining Weekly magazine
(print copy for those in South Africa and e-magazine for those outside of South Africa)
Receive daily email newsletters
Access to full search results
Access archive of magazine back copies
Access to Projects in Progress
Access to ONE Research Report of your choice in PDF format

Option 2 (equivalent of R375 a month):

All benefits from Option 1
PLUS
Access to Creamer Media's Research Channel Africa for ALL Research Reports, in PDF format, on various industrial and mining sectors including Electricity; Water; Energy Transition; Hydrogen; Roads, Rail and Ports; Coal; Gold; Platinum; Battery Metals; etc.

Already a subscriber?

Forgotten your password?

MAGAZINE & ONLINE

SUBSCRIBE

RESEARCH CHANNEL AFRICA

SUBSCRIBE

CORPORATE PACKAGES

CLICK FOR A QUOTATION